반응식
[F:1][C:2]1[CH:7]=[CH:6][C:5](/[CH:8]=[CH:9]/[C:10]2[C:18]3[C:13](=[CH:14][CH:15]=[C:16]([C:21](O)=[O:22])[C:17]=3[O:19][CH3:20])[NH:12][N:11]=2)=[CH:4][CH:3]=1.[NH2:24][CH2:25][CH:26]([OH:34])[CH2:27][N:28]1[CH2:33][CH2:32][O:31][CH2:30][CH2:29]1>>[OH:34][CH:26]([CH2:27][N:28]1[CH2:33][CH2:32][O:31][CH2:30][CH2:29]1)[CH2:25][NH:24][C:21]([C:16]1[C:17]([O:19][CH3:20])=[C:18]2[C:13](=[CH:14][CH:15]=1)[NH:12][N:11]=[C:10]2/[CH:9]=[CH:8]/[C:5]1[CH:4]=[CH:3][C:2]([F:1])=[CH:7][CH:6]=1)=[O:22]참가 물질
3
실험 절차
100 mg of 3-[(E)-2-(4-fluorophenyl)-vinyl]-4-methoxy-1H-indazole-5-carboxylic acid obtained by Example 234 and 130 mg of 1-amino-3-(morpholine-4-yl)propane-2-ol were condensed in the similar method as described in Example 44, to afford 66 mg of the title compound as colorless needle crystals.
후처리
- customcondensed in the similar method
출처 및 근거
- ORD 기록
- ord-cdbb4289407b462dab29ea96153df71a
- 출처 데이터셋
- uspto-grants-2008_09
- 특허 번호
- US07429609B2
연결된 노트
불러오는 중…